Rani Therapeutics Holdings, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-04. Between them they name 2 people, with 1 appointment and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Michelle Gilson
Director Appointment On August 1, 2026, Michelle Gilson was appointed to the Board, effective immediately, until the earlier of the Company's next annual meeting of stockholders, the appointment and qualification of her successor, or her death, resignation, or removal.
Reported
On June 29, 2026, Rani Therapeutics Holdings, Inc. (the "Company") announced the appointment of Nicholas M. Maestas as the Company's Chief Financial Officer (principal financial officer and principal accounting officer) effective as of June 29, 2026.
Departing: Svai Sanford, Chief Financial Officer
On May 12, 2026, Svai Sanford, the Company's Chief Financial Officer, advised the Company that he will resign from his position following the appointment of his successor.
Find people with the same kind of experience as the Chief Financial Officer at Rani Therapeutics Holdings, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Rani Therapeutics Holdings, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Rani Therapeutics Holdings, Inc. is in the news or changes leadership.
Get an alert when Rani Therapeutics Holdings, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Rani Therapeutics Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.